Pharma's Latest Davos Pledge: Sincere, Or Just Keeping Up Appearances?
Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.
You may also be interested in...
Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.
If in five years' time the newly launched CEPI coalition successfully produces DNA and RNA-based vaccines for use against future epidemics, then the high-profile Davos forum will really have something to crow about.
Pharma leaders in the UK and Europe have had a stormy start to the week, as the UK government revealed its aim to leave the single market and the OECD issued a loud call for drug makers to restrain their prices.